BFM
ALDX icon

Boston Financial Management’s Aldeyra Therapeutics ALDX Stock Holding History

Boston Financial Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$141K Buy
+28,248
New +$145K ﹤0.01% 334

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Boston Financial Management's ALDX Position: Q4 2024 in Review

Boston Financial Management opened a new position in Aldeyra Therapeutics (ALDX) in Q4 2024: 28,248 shares worth $141K. The stake represents ﹤0.01% of the portfolio and ranks #334 among its holdings.

118 funds tracked by Wall St. Rank hold ALDX as of Q4 2024.

  • Boston Financial Management held 28,248 shares of Aldeyra Therapeutics worth $141K as of Q4 2024.
  • Aldeyra Therapeutics was a new Boston Financial Management position in Q4 2024.
  • Aldeyra Therapeutics made up ﹤0.01% of Boston Financial Management's portfolio in Q4 2024, its #334 holding.
  • 118 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2024.

Based on Boston Financial Management's 13F filing for Q4 2024, filed 3 Feb 2025.